NASDAQ:DFFN Diffusion Pharmaceuticals (DFFN) Stock Forecast, Price & News $3.78 -0.04 (-1.05%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.74▼$3.8150-Day Range$3.77▼$5.1652-Week Range$3.55▼$8.74Volume3,502 shsAverage Volume8,030 shsMarket Capitalization$7.70 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Diffusion Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside151.7% Upside$9.50 Price TargetShort InterestHealthy0.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 stars 3.5 Analyst's Opinion Consensus RatingDiffusion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Diffusion Pharmaceuticals has a forecasted upside of 151.7% from its current price of $3.78.Amount of Analyst CoverageDiffusion Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.48% of the float of Diffusion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDiffusion Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Diffusion Pharmaceuticals has recently increased by 148.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDiffusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthDiffusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DFFN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Diffusion Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for DFFN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Diffusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diffusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Diffusion Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 9.24% of the stock of Diffusion Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Diffusion Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diffusion Pharmaceuticals is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiffusion Pharmaceuticals has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Diffusion Pharmaceuticals (NASDAQ:DFFN) StockDiffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.Read More Receive DFFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DFFN Stock News HeadlinesMay 31, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated by Analysts at StockNews.comMay 24, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Diffusion Pharmaceuticals (NASDAQ:DFFN)June 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 23, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFNMay 14, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Now Covered by StockNews.comMay 7, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Earns Hold Rating from Analysts at StockNews.comApril 20, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Now Covered by Analysts at StockNews.comApril 12, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Receives New Coverage from Analysts at StockNews.comJune 4, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.March 31, 2023 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Diffusion Pharmaceuticals Inc. MergerMarch 30, 2023 | technews.tmcnet.comDFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to ShareholdersMarch 30, 2023 | msn.comDiffusion to merge with EIP Pharma in all-stock dealMarch 30, 2023 | finance.yahoo.comEIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative DiseasesMarch 28, 2023 | americanbankingnews.comDiffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated at StockNews.comDecember 16, 2022 | markets.businessinsider.comDiffusion's Shareholder LifeSci Supports Company's Strategic Review Process And Director NomineesDecember 16, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesDecember 5, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-DealingDecember 1, 2022 | finance.yahoo.comDFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…November 15, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 14, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Sees Significant Progress in its Strategic Review ProcessOctober 15, 2022 | forbes.comDiffusion PharmaceuticalsSeptember 29, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Inc. (DFFN)August 17, 2022 | seekingalpha.comDiffusion raised to Buy at H.C. Wainwright after Q2 update on lead assetAugust 17, 2022 | finance.yahoo.comDFFN: Phase 2 GBM Trial to Initiate 2H22…August 11, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 26, 2022 | finance.yahoo.comDiffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor OxygenationJune 23, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces Positive Effects in Altitude TrialSee More Headlines DFFN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DFFN Company Calendar Last Earnings11/10/2021Today6/04/2023Next Earnings (Estimated)6/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DFFN CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone(434) 220-0718Fax434-220-0722Employees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$9.50 Low Stock Price Forecast$9.50 Forecasted Upside/Downside+151.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.51% Return on Assets-62.79% Debt Debt-to-Equity RatioN/A Current Ratio8.66 Quick Ratio8.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.98 per share Price / Book0.47Miscellaneous Outstanding Shares2,040,000Free Float2,003,000Market Cap$7.70 million OptionableNot Optionable Beta1.82 Key ExecutivesRobert J. CobuzziPresident, Chief Executive Officer & DirectorWilliam HornungChief Financial OfficerKelly ArscottDirector-Clinical OperationsHarry N. CookVice President-Clinical OperationsWilliam R. ElderSecretary & General CounselKey CompetitorsCyclacel PharmaceuticalsNASDAQ:CYCCZyVersa TherapeuticsNASDAQ:ZVSACohBarNASDAQ:CWBRNexImmuneNASDAQ:NEXIEnveric BiosciencesNASDAQ:ENVBView All Competitors DFFN Stock - Frequently Asked Questions Should I buy or sell Diffusion Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DFFN shares. View DFFN analyst ratings or view top-rated stocks. What is Diffusion Pharmaceuticals' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price objectives for Diffusion Pharmaceuticals' shares. Their DFFN share price forecasts range from $9.50 to $9.50. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price. View analysts price targets for DFFN or view top-rated stocks among Wall Street analysts. How have DFFN shares performed in 2023? Diffusion Pharmaceuticals' stock was trading at $5.0573 at the beginning of the year. Since then, DFFN shares have decreased by 25.4% and is now trading at $3.7750. View the best growth stocks for 2023 here. Are investors shorting Diffusion Pharmaceuticals? Diffusion Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,700 shares, an increase of 148.7% from the April 30th total of 3,900 shares. Based on an average daily volume of 6,900 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.5% of the company's shares are sold short. View Diffusion Pharmaceuticals' Short Interest. When is Diffusion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023. View our DFFN earnings forecast. How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by $4.00. When did Diffusion Pharmaceuticals' stock split? Diffusion Pharmaceuticals shares reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF). What is Diffusion Pharmaceuticals' stock symbol? Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN." How do I buy shares of Diffusion Pharmaceuticals? Shares of DFFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Diffusion Pharmaceuticals' stock price today? One share of DFFN stock can currently be purchased for approximately $3.78. How much money does Diffusion Pharmaceuticals make? Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $7.70 million. The company earns $-15,590,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis. How can I contact Diffusion Pharmaceuticals? Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for the company is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722. This page (NASDAQ:DFFN) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diffusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.